Academic Press Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy (Volume 18) (Cancer Sensitizing Agents for Chemotherapy, Volume 18)

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds―molecules that inhibit the growth of vessels inside a tumor―together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field. Review Presents the most recent knowledge on the use of anti-angiogenic drugs as sensitizer agents for chemotherapy From the Back Cover <p><i>Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy</i> presents updated reviews on anti-angiogenic drugs used in tumor therapy. It focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken in consideration as well as the advances made in combination therapies recently.</p> <p>The book encompasses examples of studies on the use of antiangiogenic compounds, molecules that inhibit the growth of vessels inside a tumor, together with antineoplastic drugs, in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, it discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin, and brain and circulating tumors.</p> <p>It is a valuable resource for cancer researchers, clinicians and members of biomedical field who wants to be up to date with the most recent and promising developments of the field.</p> About the Author Dr. Morbidelli’s experience is within the molecular and biochemical pharmacology of angiogenesis and microcirculation and its biological application in diseases and cancer. Through of a plethora of in vitro and in vivo models, she has contributed to the characterization of the pro- and antiangiogenic activities of designed synthetic molecules and natural products and their potential applications in angiogenesis-dependent diseases of the cardiovascular system, ocular disorders, neurovascular diseases and cancer. She co-organized with Professor Bonavida the Fourth International Workshop on “Nitric Oxide in Cancer held in Sevilla in March 13-14, 2015. The meeting addressed different topics such as NO, mutagenesis, carcinogenesis, tumor promotion and tumor growth; NO regulation of cell death pathways; NO and proliferation and epithelial-mesenchymal transition; Regulation of immune response by NO; Antitumoral activity of NO-based releasing strategies: pre-clinical studies; Antitumoral activity of NO-based releasing strategies: clinical trials.